Ginkgo Bioworks Holdings, Inc. (DNA) Stock Drops Despite Market Gains: Important Facts to Note

Company Performance - Ginkgo Bioworks Holdings, Inc. closed at $10.02, reflecting a -6.36% change from the previous day, underperforming the S&P 500's 0.03% gain [1] - Over the past month, shares of Ginkgo Bioworks have increased by 20.09%, outperforming the Medical sector's loss of 0.01% and the S&P 500's gain of 0.6% [1] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$1.8 per share, indicating a year-over-year growth of 1.1% [2] - The consensus estimate for revenue is $37 million, representing a 15.62% decrease compared to the same quarter of the previous year [2] Annual Forecast - For the entire year, Zacks Consensus Estimates predict earnings of -$5.94 per share and revenue of $173 million, showing changes of +42.66% and 0%, respectively, compared to the previous year [3] Analyst Sentiment - Recent changes to analyst estimates for Ginkgo Bioworks reflect evolving short-term business trends, with upward revisions indicating analysts' positive outlook on the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Ginkgo Bioworks as 3 (Hold) [6] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which ranks in the top 36% of all industries according to the Zacks Industry Rank [7] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]